PD-L1 blockade shows activity in MSS rectal cancer when combined with radiation and chemotherapy

▸ TREATMENT

The PRECAM-R trial demonstrated that short-course radiotherapy may create an immune-priming window in microsatellite-stable tumors, allowing PD-L1 blockade to achieve a 44.8% pathologic complete response rate. (The ASCO Post)